Download PDF
Planta Med 2012; 78(09): 874-880
DOI: 10.1055/s-0031-1298471
Biological and Pharmacological Activity
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Oxysophoridine through Intrathecal Injection Induces Antinociception and Increases the Expression of the GABAAα1 Receptor in the Spinal Cord of Mice

Guang Yang
1   Department of Pharmacology, Ningxia Medical University, Yinchuan, China
,
Jinxian Gao
2   Department of Pharmacy, the Peopleʼs Hospital of Gansu Province, Gansu, China
,
Yuexia Jia
1   Department of Pharmacology, Ningxia Medical University, Yinchuan, China
,
Lin Yan
1   Department of Pharmacology, Ningxia Medical University, Yinchuan, China
,
Jianqiang Yu
1   Department of Pharmacology, Ningxia Medical University, Yinchuan, China
,
Yuanxu Jiang
1   Department of Pharmacology, Ningxia Medical University, Yinchuan, China
› Author Affiliations
Further Information

Publication History

received 23 December 2011
revised 21 March 2012

accepted 26 March 2012

Publication Date:
24 April 2012 (online)

    Permissions and Reprints

Abstract

Our researches in recent years have shown that oxysophoridine (OSR), an alkaloid extracted from Siphocampylus verticillatus, presents antinociception through systemic and intracerebroventricular (icv) administration, and that OSR can also increase the GABA-immunopositive cells number in the central nervous system in rats. The purpose of the present study was to investigate the antinociception produced by OSR administered spinally, the interaction between OSR and GABAA receptor (GABAAR) agonists or antagonists on acute thermal nociceptive models (tail-flick test), and the possible alterations on the mRNA and protein expression of GABAAα1 receptors in the spinal cord. ICR mice were tested for their tail withdrawal response to thermal stimulation (tail-flick test). Quantitative real-time PCR and Western blot were used to inspect the influence of OSR administered by intrathecal injection (i. t.) on mRNA and protein expression of the GABAAα1 receptor in mice spinal cord by the formalin test. The experiments showed that OSR (0.13–0.25 mg/site, i. t.) significantly increased the tail withdrawal threshold with a peak effect of 68.35 % MPE at 20 min (p < 0.01). When OSR (0.06 mg/site, i. t.) was administered with gamma aminobutyric acid (GABA) (30.0 µg/site, icv) or muscimol (MUS) (0.10 µg/site, icv), the value of tail-flick latency was remarkably larger than with OSR alone (at 10 min, 45.67 % or 31.45 %, p < 0.01). Picrotoxin (PTX) and bicuculine (BIC) can significantly antagonize the antinociception of OSR. OSR (0.25 mg/site, i. t.) can increase the expression of mRNA and protein of the GABAAα1 receptor in the spinal cord (L5–L6). The results reveal that i. t. administered OSR presents effective antinociception whose action is mainly located in the spinal cord. The antinociception of OSR results from the activation of the GABAA receptor and from the regulation of the GABAAα1 receptor-mediated neurotransmission.

Key words

oxysophoridine - antinociceptive - intrathecal injection - GABAA receptor - spinal cord - Siphocampylus verticillatus - Campanulaceae
 

  • References

  • 1 Millan MJ. Descending control of pain. Neurobiology 2002; 66: 355-474
    PubMedGoogle Scholar
  • 2 Malcangio M, Bowery NG. GABA and its receptors in the spinal cord. TIPS 1996; 17: 457-462
    PubMedGoogle Scholar
  • 3 Reis G, Pacheco D, Francischi J, Castro M, Perez A, Duarte I. Involvement of GABAA receptor-associated chloride channels in the peripheral antinociceptive effect induced by GABAA receptor agonist muscimol. Eur J Pharmacol 2007; 564: 112-115
    CrossrefPubMedGoogle Scholar
  • 4 Michels G, Moss SJ. GABAA receptors: properties and trafficking. Crit Rev Biochem Mol Biol 2007; 42: 3-14
    CrossrefPubMedGoogle Scholar
  • 5 Nadeson R, Guo Z, Porter V, Gent JP, Goodchild CS. Gamma-aminobutyric acid A receptors and spinally mediated antinociception in rats. Pharmacol Exp Ther 1996; 278: 620-626
    PubMedGoogle Scholar
  • 6 Zhong R. Research and application of sophora . Yinchuan: Ningxia Peopleʼs Publishing House Press; 1985: 10-20
    Google Scholar
  • 7 Rodrigues AL, da Silva GL, Mateussi AS, Fernandes ES, Miguel OG, Yunes RA, Calixto JB, Santos AR. Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus . Life Sci 2002; 70: 1347-1358
    CrossrefPubMedGoogle Scholar
  • 8 Trentin AP, Santos AR, Miguel OG, Pizzolatti MG, Yunes RA, Calixto JB. Mechanisms involved in the antinociceptive effect in mice of the hydroalcoholic extract of Siphocampylus verticillatus . J Pharm Pharmacol 1997; 49: 567-572
    CrossrefPubMedGoogle Scholar
  • 9 Gao J, Tao L, Yu J, Jin S, Yang G, Yonghui XU, Jiang Y. The antinociceptive action of oxysophoridine and its effect on the expression of PKCγ in central nervous system of mice. Chin Pharmacol Bull 2009; 11: 1453-1456
    PubMedGoogle Scholar
  • 10 Yao W, Zhou J, Yan L, Jin S, Jiang Y. Antinociceptive effect of oxysophoridine and its mechanism. Chin Tradit Herb Drugs 2008; 4: 569-571
    PubMedGoogle Scholar
  • 11 Yan L, Jiang Y, Yao W. Experimental study of the analgesia actions of oxysophoridine. Chin Tradit Herb Drugs 2006; 7: 1061-1062
    PubMedGoogle Scholar
  • 12 Yu J, Jiang Y. Effects of oxysophoridine on Glu and GABA immuno-reaction positive neurons in cortex and hippocampus of rats. China J Chin Mater Med 2006; 10: 1611-1614
    PubMedGoogle Scholar
  • 13 Zhou J, Jiang YX, Jin S, Tao L, Liu L. Studies on analgesic effects and sites of oxymatrine carbenoxolone sodium complex. China J Chi Mater Med 2008; 33: 822-824
    PubMedGoogle Scholar
  • 14 Zhou J, Yang G, Jin S, Tao L, Yu J, Jiang Y. Oxymatrine–carbenoxolone sodium inclusion compound induces anti-nociception and increases the expression of GABAAα1 receptors in mice. Eur J Pharmacol 2010; 626: 244-249
    CrossrefPubMedGoogle Scholar
  • 15 Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol 1980; 67: 313-316
    CrossrefPubMedGoogle Scholar
  • 16 Bannon AW, Malmberg AB. Models of nociception: hot-plate, tail-flick, and formalin tests in rodents. Curr Protoc Neurosci 2007; 41: 891-896
    PubMedGoogle Scholar
  • 17 Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev 2001; 53: 597-652
    PubMedGoogle Scholar
  • 18 Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Adv Pharmacol 2006; 54: 1-27
    PubMedGoogle Scholar
  • 19 Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G. GABA (A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 2000; 101: 815-850
    CrossrefPubMedGoogle Scholar
  • 20 Bormann J. The ʼABCʼ of GABA receptors. Trends Pharmacol Sci 2000; 21: 16-19
    CrossrefPubMedGoogle Scholar
  • 21 Hammond DL. J. J. Bonica Lecture-2001: role of spinal GABA in acute and persistent nociception. Reg Anesth Pain Med 2001; 26: 551-557
    PubMedGoogle Scholar
  • 22 Munro G, Ahring PK, Mirza NR. Developing antinociceptives by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol Sci 2009; 30: 453-459
    CrossrefPubMedGoogle Scholar
  • 23 Sieghart W. Structure, pharmacology, and function of GABAA receptor subtypes. Adv Pharmacol 2006; 54: 231-263
    PubMedGoogle Scholar
  • 24 Suh HW, Song DK, Huh SO, Lee KC, Kim YH. Differential potentiative effects of GABA receptor agonists in the production of antinociception induced by morphine and p-endorphin administered intrathecally in the mouse. Life Sci 2000; 66: 61-69
    PubMedGoogle Scholar
  • 25 Natsu K, Fumihiko H, Toshikatsu Y. Does intravenous administration of GABAA receptor antagonists induce both descending antinociception and touch-evoked allodynia?. Pain 1998; 76: 327-336
    CrossrefPubMedGoogle Scholar
  • 26 Knabl J, Witschi R, Hösl K, Reinold H, Zeilhofer UB, Ahmadi S, Brockhaus J, Sergejeva M, Hess A, Brune K, Fritschy JM, Rudolph U, Möhler H, Zeilhofer HU. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 2008; 451: 330-334
    CrossrefPubMedGoogle Scholar
  • 27 Raschid MH, Ueda H. Neuropathy-specific analgesic action of intrathecal nicotinic agonists and its spinal GABA-mediated mechanism. Brain Res 2002; 953: 53-62
    CrossrefPubMedGoogle Scholar
  • 28 Edwards M, Serrao JM, Gent JP, Goodchild CS. On the mechanism by which midazolam causes spinally mediated analgesia. Anesthesiology 1990; 73: 273-277
    CrossrefPubMedGoogle Scholar
  • 29 Wang Y, Deng X, You X, Liu S, Zhao Z. Involvement of GABA and opioid peptide receptors in sevoflurane-induced antinociception in rat spinal cord. Acta Pharmacol Sin 2005; 26: 1045-1048
    CrossrefPubMedGoogle Scholar
  • 30 Whiting PJ, Bonnert TP, McKernan RM, Farrar S, Le Bourdellès B, Heavens RP, Smith DW, Hewson L, Rigby MR, Sirinathsinghji DJ, Thompson SA, Wafford KA. Molecular and functional diversity of the expanding GABA-A receptor gene family. Ann NY Acad Sci 1999; 30: 645-653
    PubMedGoogle Scholar
  • 31 Nutt D. GABAA receptors: subtypes, regional distribution, and function. J Clin Sleep Med 2006; 2: S7-S11
    PubMedGoogle Scholar
  • 32 Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, Braestrup C, Bateson AN, Langer SZ. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998; 50: 291-313
    PubMedGoogle Scholar
  • 33 Yi Z, Yang G, Yan L, Jia Y, Jiang Y. Effect of oxysophoridine on amino acid content in spinal cord of rats with formalin-induced pain. Chin Pharm J 2011; 46: 826-829
    PubMedGoogle Scholar
  • 34 Gao J, Yi Z, Yang G, Yan L, Tao L, Gao S, Pan Q, Jiang Y. Effect of the down-regulation of GAT-1 on analgesic action of oxysophoridine. China J Chin Mater Med 2011; 36: 32-36
    PubMedGoogle Scholar